India Considers Different Regulation Policies For APIs, Other drugs
This article was originally published in PharmAsia News
India regulators plan to separate active pharmaceutical ingredients from other drugs and adopt a policy for each in a bid to gain back the nation's leadership in bulk-drug production that was lost to China.
You may also be interested in...
Swiss biotech Molecular Partners will receive upfront payment of CHF 60m, including equity.
Just as the MDR and IVDR are being implemented, increasing regulatory divergence in Europe is a growing danger to patient safety throughout the EU, not least through increasing costs and impacting device availability.
It’s time to focus on how the diagnostics sector will comply with the EU’s IVD Regulation. TÜV SÜD expert, Andreas Stange, explains why the IVD industry could be in trouble and what must be done now.